ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status

European Journal of Haematology

Volumn 85, Issue 4, 2010, Pages 361-362

  Hämäläinen, Mauri ^a   Juvonen, Vesa ^a   Häikiö, Satu ^b   Lakkala, Taina ^b   Johansson, Janita ^a   Pelliniemi, Tarja Terttu ^a   Salmi, Toivo T ^a   Remes, Kari ^a   Kairisto, Veli ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR ERG; CD135 ANTIGEN; ERG PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ETS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BONE MARROW; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CYTOPENIA; FEMALE; GENE MUTATION; HUMAN; HYPOPLASIA; IRON DEFICIENCY ANEMIA; KARYOTYPE; LETTER; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; THROMBOCYTOPENIA; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; INFANT; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; SURVIVAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-ETS; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; YOUNG ADULT;

EID: 77956955123     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01483.x     Document Type: Letter

References (9)

1. Marcucci G, Baldus CD, Ruppert AS, et al. Overexpression of the ETS-related gene ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005 36 : 9234 9242.
2. Marcucci G, Maharry K, Whitman SP, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2007 25 : 3337 3343.
3. Santamaria CM, Chillon MC, Garcia-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009 114 : 148 152.
4. Santamaria C, Chillon MC, Garcia-Sanz R, et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival on intermediate-risk acute myeloid leukemia (AML). Ann Hematol 2010 89 : 453 458.
5. Metzeler KH, Dufour A, Benthaus T, et al. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009 27 : 5031 5038.
6. Baldus CM, Liyanarachchi S, Mrozek K, et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA 2004 101 : 3915 3920.
7. Langebrake C, Klusmann J-H, Wortman K, Kolar M, Puhlmann U, Reinhardt D. Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome. Haematologica 2006 91 : 1473 1480.
8. Hämäläinen MM, Kairisto V, Juvonen V, Johansson J, Auren J, Kohonen K, Remes K, Salmi TT, Helenius H, Pelliniemi TT. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur J Haematol 2008 80 : 201 207.
9. Loughran SJ, Kruse EA, Hacking DF, et al. The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 2008 9 : 810 819.